



August 27, 2012

## **ImmunoCellular Therapeutics to Present at Two September 2012 Investor Conferences**

LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that John S. Yu, MD, Interim Chief Executive Officer, will present a corporate overview and business update at the BioCentury and Thomson Reuters Newsmakers in the Biotech Industry Conference on September 7, 2012 at 11:30 am ET at the Millennium Broadway Hotel in New York City, and at the Rodman & Renshaw Annual Global Investment Conference on September 10, 2012 at 4:30 pm ET at the Waldorf-Astoria Hotel in New York City.

To access the live audio webcast of these presentations, please log on through a link located in the Investor Relations section of ImmunoCellular's website at [www.imuc.com](http://www.imuc.com), under the Investors, Webcasts & Presentations tab. A replay of the webcasts will be available one hour after the conclusion of the live events.

### About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. To learn more about ImmunoCellular, please visit [www.imuc.com](http://www.imuc.com).

### Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT- 107 can be further successfully developed or commercialized. Additional risks and uncertainties are described in IMUC's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise.

### **Contact Information:**

ImmunoCellular Therapeutics, Ltd.  
CEOcast, Inc.  
James Young  
Investor Relations  
Tel: (212) 732-4300  
Email: [jyoung@ceocast.com](mailto:jyoung@ceocast.com)

Source: ImmunoCellular Therapeutics, Ltd.